Korean J Pancreas Biliary Tract.
2019 Apr;24(2):61-67. 10.15279/kpba.2019.24.2.61.
Metabolic Profiling of Plasma from Pancreatic Cancer Patients in Korea
- Affiliations
-
- 1Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea.
- 2Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Korea.
- 3Division of Hematooncology, Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea. leonkim80@pusan.ac.kr
- 4Division of Gastroenterology, Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea.
- 5Department of Clinical Pharmacology and Therapeutics, Pusan National University Hospital, Busan, Korea.
- 6Department of Family Medicine, Pusan National University College of Medicine, Busan, Korea.
- 7Clinical Trial Center, Pusan National University Hospital, Busan, Korea.
- KMID: 2448662
- DOI: http://doi.org/10.15279/kpba.2019.24.2.61
Abstract
- BACKGROUND/AIMS
Pancreatic cancer (PC) patients have poor prognoses because this cancer is typically diagnosed at an advanced stage and the therapeutic options are limited. We examined the potential of metabolic profiling for early diagnosis and identification of potential therapeutic targets.
METHODS
Ten patients and 10 healthy volunteer controls older than 20 years of age were enrolled between May and December 2015. The patients were confirmed to have pancreatic ductal adenocarcinoma cytologically or histologically. Blood plasma samples were derivatized and analyzed by gas chromatography mass spectrometry (GC-MS). Untargeted GC-MS data were analyzed using statistical methods, including Wilcoxon rank-sum test and principal component analyses.
RESULTS
L-lysine was 1.36-fold higher in patients than in healthy controls (p<0.05). L-leucine was 0.63-fold lower (p<0.01) and palmitic acid was 0.93-fold lower (p<0.5) in patients than in controls. Orthogonal partial least squared-discriminant analysis revealed significant differences between the patients and controls.
CONCLUSIONS
This study suggests that the metabolic profiles of patients with PC are distinct from those of the healthy population. Further studies are required to develop methods for early diagnosis and identify therapeutic targets.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Quantification of Plasma DNA as a Tumor Marker in Patients with Pancreatic Cancer
- MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens
- Changes in Dietary Intake, Body Weight, Nutritional Status, and Metabolic Rate in a Pancreatic Cancer Patient
- Adjuvant Therapy of Pancreatic Cancer
- Prophylaxis of Venous Thromboembolism in Patients with Pancreatic Cancer
